Effects of Semaglutide on CKD in Patients With Type 2 Diabetes

被引：0
|
作者：
Kotwal, Sradha S. [1 ,2 ]
Perkovic, Vlado [1 ,3 ]
机构：
[1] Univ New South Wales, George Inst Global Hlth, Renal & Metab Div, Sydney, NSW, Australia
[2] Prince Wales Hosp, Dept Nephrol, Sydney, NSW, Australia
[3] Univ New South Wales, Fac Med, Sydney, NSW, Australia
来源：
KIDNEY INTERNATIONAL REPORTS | 2025年 / 10卷 / 02期
关键词：
KIDNEY; OUTCOMES; GLP-1;
D O I：
10.1016/j.ekir.2024.11.1365
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：287 / 290
页数：4
相关论文
共 50 条
  • [41] ORAL SEMAGLUTIDE: THE INNOVATION IN TYPE 2 DIABETES MANAGEMENT
    Shestakova, Marina V.
    Shamkhalova, Minara Sh.
    Galstyan, Gagik R.
    Ruyatkina, Ludmila A.
    Suplotova, Ludmila A.
    DIABETES MELLITUS, 2021, 24 (03): : 273 - 281
  • [42] Semaglutide is effective in type 2 diabetes and obesity with schizophrenia
    Noda, Kaoru
    Kato, Takehiro
    Nomura, Nao
    Sakai, Mayu
    Kubota, Sodai
    Hirose, Tokuyuki
    Liu, Yanyan
    Takahashi, Yoshihiro
    Takao, Ken
    Mizuno, Masami
    Hirota, Takuo
    Suwa, Tetsuya
    Horikawa, Yukio
    Yabe, Daisuke
    DIABETOLOGY INTERNATIONAL, 2022, 13 (04) : 693 - 697
  • [43] Oral Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes
    Zweck, Elric
    Westenfeld, Ralf
    Szendroedi, Julia
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (21): : 2075 - 2076
  • [44] Effects of Dapagliflozin on Anemia in Patients With CKD With or Without Type 2 Diabetes: A Pre-Specified Analysis of the DAPA-CKD Trial
    Heerspink, Hiddo J. L.
    Koshino, Akihiko
    Schechter, Meir
    Vart, Priya
    Jongs, Niels
    Chertow, Glenn
    Toto, Robert D.
    Rossing, Peter
    Correa-Rotter, Ricardo
    McMurray, John
    Langkilde, Anna Maria
    Wheeler, David C.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 43 - 43
  • [45] Response to "Effects of semaglutide on cardiovascular risk factors and eating behaviors in type 2 diabetes"
    Cheema, Muhammad Rafay Shahzad
    Kumar, Satesh
    ACTA DIABETOLOGICA, 2023, 60 (05) : 715 - 716
  • [46] Response to "Effects of Semaglutide on Cardiovascular Risk Factors and Eating Behaviors in Type 2 Diabetes"
    Venjhraj, F. N. U.
    Kumar, Mukesh
    Ram, Meva
    CURRENT PROBLEMS IN CARDIOLOGY, 2023, 48 (10)
  • [47] Response to “Effects of semaglutide on cardiovascular risk factors and eating behaviors in type 2 diabetes”
    Muhammad Rafay Shahzad Cheema
    Satesh Kumar
    Acta Diabetologica, 2023, 60 : 715 - 716
  • [48] Oral semaglutide: an innovative paradigm in the management of cardiovascular risk in patients with Type 2 diabetes
    Temporelli, Pier Luigi
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2025, 27 : i1 - i5
  • [49] A Significant Effect of Oral Semaglutide on Cardiovascular Risk Factors in Patients With Type 2 Diabetes
    Yanai, Hidekatsu
    Hakoshima, Mariko
    Adachi, Hiroki
    Katsuyama, Hisayuki
    CARDIOLOGY RESEARCH, 2022, 13 (05) : 303 - 308
  • [50] Efficacy of Semaglutide in Overweight and Obese Patients with Type 1 Diabetes
    Garg, Satish K.
    Kaur, Gurleen
    Haider, Zehra
    Rodriquez, Erika
    Beatson, Christie
    Snell-Bergeon, Janet
    DIABETES TECHNOLOGY & THERAPEUTICS, 2024, 26 (03) : 184 - 189
12345